Payment overview · 2025
General Payments
$542.45
22 reported records · 12 companies
Healthcare provider profile · identity verified
Sai Avula, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DOTHAN, AL · NPI 1467441741
Verified facts
What the public records show
CMS Open Payments records show Sai Avula, M.D. received $542.45 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 35.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $193.41 | 35.6% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$64.78 | 11.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.82 | 8.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.38 | 8.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.24 | 6.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.89 | 5.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $31.50 | 5.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.09 | 4.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $21.84 | 4.0% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $17.44 | 3.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.34 | 3.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.72 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $542.45 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.41 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $44.54 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $30.80 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $8.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 178 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 234 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 125 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 280 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 128 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
234 | 78 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
128 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
125 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
113 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
280 | 65 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 1116 | 360 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1048 | 218 |
| Amlodipine Besylate | Amlodipine Besylate | 914 | 303 |
| Gabapentin | Gabapentin | 704 | 263 |
| Atorvastatin Calcium | Atorvastatin Calcium | 667 | 249 |
| Pantoprazole Sodium | Pantoprazole Sodium | 646 | 237 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 638 | 204 |
| Omeprazole | Omeprazole | 571 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 519 | 142 |
| Pravastatin Sodium | Pravastatin Sodium | 401 | 120 |
| Metformin Hcl | Metformin Hcl | 381 | 120 |
| Meloxicam | Meloxicam | 376 | 143 |
| Fluticasone Propionate | Fluticasone Propionate | 368 | 143 |
| Carvedilol | Carvedilol | 364 | 119 |
| Furosemide | Furosemide | 362 | 138 |
| Tamsulosin Hcl | Tamsulosin Hcl | 360 | 120 |
| Metoprolol Tartrate | Metoprolol Tartrate | 352 | 136 |
| Duloxetine Hcl | Duloxetine Hcl | 351 | 113 |
| Zolpidem Tartrate | Zolpidem Tartrate | 332 | 48 |
| Trazodone Hcl | Trazodone Hcl | 297 | 111 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 285 | 118 |
| Ozempic | Semaglutide | 280 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 277 | 91 |
| Clopidogrel | Clopidogrel Bisulfate | 257 | 88 |
| Farxiga | Dapagliflozin Propanediol | 234 | 78 |
| Lisinopril | Lisinopril | 228 | 77 |
| Montelukast Sodium | Montelukast Sodium | 228 | 74 |
| Potassium Chloride | Potassium Chloride | 225 | 69 |
| Telmisartan | Telmisartan | 221 | 56 |
| Clonidine Hcl | Clonidine Hcl | 214 | 87 |
| Hydralazine Hcl | Hydralazine Hcl | 213 | 72 |
| Allopurinol | Allopurinol | 186 | 58 |
| Sertraline Hcl | Sertraline Hcl | 179 | 59 |
| Eliquis | Apixaban | 178 | 51 |
| Tramadol Hcl | Tramadol Hcl | 170 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 155 | 26 |
| Pregabalin | Pregabalin | 154 | 49 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 152 | 49 |
| Finasteride | Finasteride | 144 | 51 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 141 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 58 |
| Bumetanide | Bumetanide | 138 | 62 |
| Azithromycin | Azithromycin | 130 | 102 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 128 | 42 |
| Linzess | Linaclotide | 126 | 50 |
| Mounjaro | Tirzepatide | 125 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 35 |
| Clonazepam | Clonazepam | 121 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 121 | 32 |
| Donepezil Hcl | Donepezil Hcl | 119 | 45 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 119 | 80 |
| Trulicity | Dulaglutide | 113 | 29 |
| Methocarbamol | Methocarbamol | 112 | 44 |
| Alprazolam | Alprazolam | 100 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 48 |
| Jardiance | Empagliflozin | 96 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 96 | 37 |
| Atenolol | Atenolol | 94 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 94 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 92 | 70 |
| Buspirone Hcl | Buspirone Hcl | 89 | 30 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 86 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 29 |
| Prednisone | Prednisone | 81 | 48 |
| Glimepiride | Glimepiride | 80 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 22 |
| Famotidine | Famotidine | 76 | 35 |
| Irbesartan | Irbesartan | 73 | 17 |
| Propranolol Hcl | Propranolol Hcl | 71 | 21 |
| Xarelto | Rivaroxaban | 70 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 69 | 29 |
| Nitroglycerin | Nitroglycerin | 68 | 37 |
| Ondansetron Odt | Ondansetron | 67 | 30 |
| Colchicine | Colchicine | 63 | 25 |
| Mirtazapine | Mirtazapine | 63 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 27 |
| Metformin Hcl Er | Metformin Hcl | 59 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 47 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 33 |
| Celecoxib | Celecoxib | 54 | 24 |
| Meclizine Hcl | Meclizine Hcl | 54 | 26 |
| Midodrine Hcl | Midodrine Hcl | 54 | 32 |
| Spironolactone | Spironolactone | 54 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 16 |
| Ranolazine Er | Ranolazine | 53 | 23 |
| Topiramate | Topiramate | 53 | 15 |
| Levetiracetam | Levetiracetam | 52 | 17 |
| Nifedipine Er | Nifedipine | 52 | 18 |
| Entresto | Sacubitril/Valsartan | 51 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 24 |
| Memantine Hcl | Memantine Hcl | 47 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 15 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | 19 |
| Promethazine Hcl | Promethazine Hcl | 44 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 11 |
| Levemir Flexpen | Insulin Detemir | 43 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 13 |
| Glipizide | Glipizide | 41 | 12 |
| Alendronate Sodium | Alendronate Sodium | 40 | 17 |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 22 |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | 12 |
| Baclofen | Baclofen | 35 | 13 |
| Fluconazole | Fluconazole | 35 | 17 |
| Novolog Flexpen | Insulin Aspart | 35 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | 15 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 23 |
| Simvastatin | Simvastatin | 33 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Fentanyl | Fentanyl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 14 |
| Hydrocortisone | Hydrocortisone | 32 | 16 |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Diazepam | Diazepam | 30 | 15 |
| Methylprednisolone | Methylprednisolone | 30 | 27 |
| Digoxin | Digoxin | 29 | 11 |
| Nystatin | Nystatin | 29 | 20 |
| Temazepam | Temazepam | 29 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | 12 |
| Humalog Kwikpen U-200 | Insulin Lispro | 28 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 28 | 25 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | 11 |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | 11 |
| Valacyclovir | Valacyclovir Hcl | 24 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 18 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $542.45 · 22 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, COLLAGENASE SANTYL, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, Kerendia, Korlym, MINIMED 780G, MOUNJARO, NURTEC ODT, Omnipod, Ozempic, Rybelsus, SHINGRIX, SYMPLICITY G3, TRELEGY ELLIPTA, Veozah, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error